(Q45945682)

English

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

scientific article published on 30 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

colorectal cancer

1 reference

based on heuristic

inferred from title

Armando Santoro

1 reference

ORCID Public Data File 2021

author name string

M Ychou

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

W Hohenberger

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

S Thezenas

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

M Navarro

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

J Maurel

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

C Bokemeyer

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

E Shacham-Shmueli

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

F Rivera

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

C Kwok-Keung Choi

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

A Santoro

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

publication date

30 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

20

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

12

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

1964-1970

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Surgical management of hepatic metastases from colorectal malignancies.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Predictors of survival after hepatic resection among patients with colorectal liver metastasis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP236

21 January 2018

Identifiers

10.1093/ANNONC/MDP236

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19567451

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45945682&oldid=2147396035"